Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 33–38

Sodium Deoxyribonucleate Prevents Radiation Cystitis in Uterine or Cervical Cancer Patients

P.I. Skopin1, A.A. Ivashin1, Yu.A. Skopina1, Yu.V Kozina 2, R. A. Zukov 2,3 , A.V. Siprov1, E.V. Slepov2

1N.P. Ogarev National Research Mordovia State University, Saransk, Russia.

2A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncological Dispensary, Krasnoyarsk, Russia

3V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia

Contact person: Artem Aleksandrovich Ivashin: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Results: To develop a method for reducing the frequency and severity of early radiation reactions in patients with cancer of the uterus or cervix.

Material and methods: We analyzed the results of treatment of 60 patients with cancer of the uterus and cervix, patients received a postoperative course of external beam radiotherapy combined with the intramuscular administration of the Derinat® radioprotector (sodium deoxyribonucleate); in the second arm, they received a postoperative course of external beam radiotherapy and standard therapy in case of radiation cystitis. The assessment of radiation reactions severity was performed with the EORTC QLQ-C30 criteria, WBC count, IPSS scale, urine analysis and cystoscopic examination evaluated with the developed by us scale.

Results: Evaluation of the quality of life in patients with cervical or uterine cancer at the final stage of treatment using the IPSS scale showed that in the arm of patients with sodium deoxyribonucleate, there was a 30.4 % (p> 0.05) decrease in the symptoms of urinary disorders. The use of the radioprotector sodium deoxyribonucleate also statistically significantly reduced the incidence of radiation cystitis by 73 %. According to cystoscopy, the total bladder injury score at the end of treatment was 147 % lower. The number of leukocytes in the urine analysis at the end of treatment was 116.3 % lower (p≤0.01) in those who received sodium deoxyribonucleate

Conclusion: The data obtained indicate the radioprotective efficacy of sodium deoxyribonucleate and make it possible to recommend its intramuscular administration to patients with cancer of the uterus and cervix against the background of external beam radiation therapy to reduce the frequency and severity of acute radiation cystitis in patients with cancer of the uterus or cervical cancer receiving external beam radiation therapy.

Key words: radiation cystitis, uterine cancer, cervical cancer, sodium deoxyribonucleate

For citation: Skopin PI, Ivashin AA,  Skopina Yu.A,  Kozina YuV,  Zukov R A.  Siprov AV, Slepov EV. Sodium Deoxyribonucleate Prevents Radiation Cystitis in Uterine or Cervical Cancer Patients. Medical Radiology and Radiation Safety. 2021;66(5):30-35.

DOI: 10.12737/1024-6177-2021-66-5-33-38

References

1. Eds. Kaprin AD, Starinskiy VV, Shahzadova AO. The Status of Cancer Care for the Population of Russia in 2019. Moscow, Herzen Moscow Scientific Research Institute of Oncology (MNOI) Publ., 2020. 239 p. (In Russian).

2. Bouchard M, Nadeau S, Gingras L, Raymond P, Beaulieu F, Beaulieu L, Germain I. Clinical Outcome of Adjuvant Treatment of Endometrial Cancer Using Aperture-Based Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics. 2008;71;5:1343–1350. DOI:10.1016/j.ijrobp .2007.12.004.

3. Shakespeare TP, Lim KH, Lee KM, Back MF, Mukherjee R, Lu JD. Phase II Study of the American Brachytherapy Society Guidelines for the Use of High-Dose Rate Brachytherapy in the Treatment of Cervical Carcinoma: Is 45–50.4 Gy Radiochemotherapy Plus 31.8 Gy in Six Fractions High-Dose Rate Brachytherapy Tolerable? Int. J. Gynecol. Cancer. 2006;16; 1:277–282.

4. Yalman D, Arican A, Ozsaran Z, Celik OK, Yurut V, Esassolak M., et al. Evaluation of Morbidity after External Radiotherapy and Intracavitary Brachytherapy in 771 Patients with Carcinoma of the Uterine Cervix or Endometrium. Eur. J. Gynaecol. Oncol. 2002;23;1:58–62.

5. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The Impact of Overactive Bladder, Incontinence and Other Lower Urinary Tract Symptoms on Quality of Life, Work Productivity, Sexuality and Emotional Well-Being in Men and Women: Results from the EPIC Study. BJU Int. 2008;101; 11:1388–1395.

6. Jereczek-Fossa BA, Badzio A, Jassem J. Factors Determining Acute Normal Tissue Reactions During Postoperative Radiotherapy in Endometrial Cancer: Analysis of 317 Consecutive Cases. Radiother. Oncol. 2003;68;1:33–39.

7.  Nordling J, Fall M, Hanno P. Global Concepts of Bladder Pain Syndrome (Interstitial Cystitis). World Journal of Urology. 2011;30;4:457–464. doi:10.1007/s00345-011-0785-x.

8. Pavlidakey PG, MacLennan GT. Radiation Cystitis. The Journal of Urology. 2009;182;3:1172–1173. doi:10.1016/j.juro.2009.06.034.

9. Sycheva IV, Pasov VV, Kurpesheva AK. Conservative Methods of Treatment of Local Radiation Injuries Formed as a Result of Combined Radiotherapy and Brachytherapy of Prostate Cancer. Siberian Journal of Oncology. 2012;53;5:57-60 (In Russian).

10. Kulaev MT, Almyashev AZ, Meltsaev GG, Shchukin S.A. External1. Application of Derinat in the Treatment of Radiation Ulcers and Malignant Tumors of Visible Localizations. Creative Surgery and Oncology. 2009;1:35-39 (In Russian).

11. Zukov RA, Kozina YV, Kozin VA, Slepov EV. Optimization of Radiation Therapy in Patients with Prostate Cancer. Siberian Medical Review. 2018;2:110-105. DOI: 10.20333/2500136-2018-2-100-105 (In Russian).

12. Minaev NN, Ivanova MN, Bugrimov DY, Klimovich AA. Clinical Efficacy of Agonist Toll-Like Receptor 9 on the Process of Reparations after Loop Conization (LEEP) of the Cervix. Journal of Obstetrics and Women’s Diseases. 2016;5:101-112. DOI: 10.17816/JOWD655101-112 (In Russian).

13. Filatov OY, Kashaeva OV, Bugrimov DYu., Klimovich AA. Morphophysiological Principles of the Immunological Action of Eukaryotic DNA. Russian Journal of Immunology. 2013;7;16:385-390 (In Russian).

14. Kaplina EN. Derinat is a Domestic Natural Immunomodulator. Advances in Current Natural Science. 2003;5:63-64 (In Russian).

 PDF (RUS) Full-text article (in Russian)

 

Conflict of interest. The author declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors

Article received: 17.02.2021. 

Accepted for publication: 20.04.2021.